Prexasertib: an investigational checkpoint kinase inhibitor for the treatment of high-grade serous ovarian cancer
- 25 June 2020
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Investigational Drugs
- Vol. 29 (8) , 779-792
Abstract
Patients with high-grade serous ovarian cancer (HGSOC) have a poor prognosis, and current chemotherapy regimens for treating advanced disease are far from satisfactory. Prexasertib (LY2606368) is a...Keywords
This publication has 94 references indexed in Scilit:
- Cyclin-Dependent Kinase Suppression by WEE1 Kinase Protects the Genome through Control of Replication Initiation and Nucleotide ConsumptionMolecular and Cellular Biology, 2012
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian CancerJournal of Clinical Oncology, 2012
- Integrated genomic analyses of ovarian carcinomaNature, 2011
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancerGynecologic Oncology, 2011
- Clinical Trials in Recurrent Ovarian CancerInternational Journal of Gynecological Cancer, 2011
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesisNature Reviews Molecular Cell Biology, 2010
- Synthetic lethal targeting of PTEN mutant cells with PARP inhibitorsEMBO Molecular Medicine, 2009
- The checkpoint response to replication stressDNA Repair, 2009
- Chk1 Requirement for High Global Rates of Replication Fork Progression during Normal Vertebrate S PhaseMolecular and Cellular Biology, 2006